Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Analysts at Jefferies Group decreased their FY2018 earnings estimates for shares of Ultragenyx Pharmaceutical in a report issued on Monday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will earn ($6.88) per share for the year, down from their previous estimate of ($6.67). Jefferies Group currently has a “Buy” rating and a $72.00 target price on the stock. Jefferies Group also issued estimates for Ultragenyx Pharmaceutical’s FY2019 earnings at ($6.43) EPS, FY2020 earnings at ($4.94) EPS and FY2021 earnings at ($2.12) EPS.

Several other research firms have also recently issued reports on RARE. Barclays upped their price objective on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Tuesday. Canaccord Genuity set a $80.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. J P Morgan Chase & Co set a $76.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, August 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $69.00 price objective (down from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical has a consensus rating of “Buy” and an average price target of $72.40.

Ultragenyx Pharmaceutical (NASDAQ RARE) traded down $1.80 during mid-day trading on Wednesday, reaching $49.96. The company had a trading volume of 1,220,000 shares, compared to its average volume of 438,033. Ultragenyx Pharmaceutical has a fifty-two week low of $44.02 and a fifty-two week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.87). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. The business’s revenue was up 81.8% compared to the same quarter last year. During the same period last year, the company posted ($1.64) earnings per share.

Several large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 7.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares in the last quarter. Aperio Group LLC increased its stake in shares of Ultragenyx Pharmaceutical by 8.4% in the 2nd quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after purchasing an additional 299 shares in the last quarter. Amalgamated Bank increased its stake in shares of Ultragenyx Pharmaceutical by 7.6% in the 2nd quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 352 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 12.0% in the 2nd quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 365 shares in the last quarter. Hedge funds and other institutional investors own 94.13% of the company’s stock.

WARNING: “FY2018 EPS Estimates for Ultragenyx Pharmaceutical Inc. (RARE) Reduced by Jefferies Group” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/06/fy2018-eps-estimates-for-ultragenyx-pharmaceutical-inc-rare-reduced-by-jefferies-group.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.